lilly's going where the compounders are, online. this offer available through their dtc platform, lilly direct. you need a prescription, but they already have a telehealth component, so, you could go to lilly direct, get a prescription, and get it filled all in one place. now, this still does cost more than a vial -- this does cost more than the compounded versions, so, will this completely disrupt that market, probably not. but it's definitely something we want to watch here, tyler. >> so, as i understand it, unlike the -- so new, i hardly can call it traditional. but the other version of zepbound, which is injected with a kind of injector pen, this requires you, does it not, to use an actual syringe and you have to use a new one every time, right? >> yeah, so, the pen, which is the typical format, like it sounds, it's a pen, you click the button, and it injects you with the medicine. you have to take the vial, draw up the medicine with the syringe and inject yourself with a needle. it's a little bit more complicated, but lilly is

that's not the case for eli lilly. we're not expecting significant price pressure in the u.s., because it's a duopoly between these two large companies. and so, when we think about the u.s. market, you know, we think prices are going to remain, you know, strong in coming years. once again, there's greater demand and supply. it wouldn't make sense for lilly to be cutting prices. with respect to looking further forward, certainly when competition enters the market late decade, there could be greater pricing pressure, but we're not going to see meaningful competition enter until possibly 2028, 2029, starting in those years. with regard to the oral that lilly has, the first phase three results will start to be reported in the spring of next year. that's going to be an oral chemical pill that is far cheaper and easier to manufacture, and we're looking forward to them rolling that out and blanketing the world with it. >> you mentioned cheaper to manufacture, but in terms of margin, will it actually be a lot better, you know,

lilly is a sim slar situation.not a tech stock, but momentum, up and looks like that on the surface. it's a momentum play. >> it has a megacap. it does have a huge market capitalization. >> yeah. a secular growth story that investors are trying to get their arms around not different than ai. bob pisani, thank you. that was great. >>> let's get more perspective on this volatile market. our next guest says the bull market remains intact despite the recent losses. joining us is mona from edward jones and senior investment strategist. >> great to be here. >> garden variety correction even if it came ferociously and fiercely in the course of a day or two. >> yeah. look this correction was driven in two parts. one we had a growth scare. clearly the jobs report on friday triggered that. this liquidity technical swear with the bank of japan raising rates. that part of it has been addressed. the bank of japan said look, we're not going to raise rates further in this period of volatility. now what everybody is watching is, i

eli lilly has been ramping up supply.expectations will be reset, eli lilly may be better addressing the supply problem short-term than novo nordisk. >> will it be better with mounjaru? >> that would suggest wegovy is on the shortage list. they are better at getting supply in the market, but taking a different approach. wegovy is offered to patients that can continue the trial. whereas lilly products are still dealing with production. >> two new weight-loss drugs coming out next year. one is an oral one. the other may have the most efficacy as all of them. i had to think of the word. r&d, we have gone back and forth they are spending too much. is lilly spending enough with the r &yad? >> looking at the neurological side and eli lilly is an early leader in the oral segment, but they are thinking about other applications with alzheimer's with early trial data that is encouraging. we think as they look at applications beyond weight loss, it will go up. many people are looking at applications beyond weight loss. you have novo

but two is eli lilly. this morning lilly reported a quarter with 11.3 billion in sales when wall street was looking for less than 10 billion while raising their full year sales guidance to 46 billion. $3 billion above expectations. in large part thanks to these wondrous glp-1 drugs. it was a tour de force quarter, one where they highlighted so many different indications for mounjaro and depositionbound, those are different versions, same stuff, that you have to believe your insurance will cover it. it was also so good the insurers genuinely may not have a choice even if they need to pay through the nose for this stuff. lilly's results had nothing to do with mortgage rates or jay powell or a drug etf that might have capped your gains if you chose to play it that way. much better to just go with eli lilly, which is best in breed. it's not like nobody saw this coming. if you went with best in breed you were up 9.5% today. [ applause ] i know this morning i was very concerned that lilly could miss numbers, i t

lilly's ceo today telling us the company will talk to regulators will next steps, skeptical that lilly can get approval specifically for pre diabetes but saying if it does that would be a significant opportunity. either way, lilly's ceo arguing these results could help make the case for more insurance coverage. >> the dual acting inhibitor actually not only keep you thinner, but keep you healthier. and we're beginning to learn that it keeps you healthier. so i think we need to argue for that and both the federal government doesn't pay for these, many employers don't, they should. this is going to save money for our country in the long term and keep people living a healthier, longer life. >> this is part of lilly's plan to show that the health benefits go beyond simply losing weight. we will look to hear more from them. >> angelica with the latest on a big story in health care. >>> our next guest says the results could position zepbound as a best in class weight loss drug. let's get more with dr. patel. this is huge. 94% possible reduction in type 2 diabetes risks. just how much does th

we've been talking so much about eli lilly, the clear leader, right?are index within the s&p is up 14% so far, so very respectable. let's bring in katie stockton, tech technician, and she has interesting thoughts whether we think names like eli lilly and novo nordisk, the ones that are anti-obesity, are the ones that will still be leading 6 to 12 months from now. katie? >> i think, dom, a shift in leadership is likely here. i say that in part for top-down reasons. when we sue market conditions develop, the winners, the leaders tend to be penalized in that environment. we are seeing for a seesaw corrections for the major indices. that would likely hit the likes of lilly and novo, harder than the laggards in that space. we've noticed some real recovery rallies to suggest they're on the verge of turning the corner. it comes at the same time we've seen very subtle loss of long-term up side. >> so you're not so much down on eli lilly, if i'm understanding you correctly, as saying eli lilly may get caught more than others in a market downdraft, that is a. b,

lilly.illpower and they can not maintain a workout. hens why americans are prone to diabetes. we have been hearing about there's drugs for some time. there was always skepticism about how well they performed long-term, long-term, today we got the results of 176 week trial on lilly. it a game changer for fighting diabetes and average% losing 23% of their body weight. the fd alikely will clear the drug. because there is no turn, i don't see how the companies can avoid paying for it on the wonder drugs, so many are worried. i feel better about this. as they told us this morning, the drug will save the system a lot of money. >> i think the question two years ago was, do these drugs, does the duel acting inhibitor actually not only keep you thinner but healthier? and we are beginning to learn that it keeps you healthier. the federal government does not pay for these, many employees don't, they should. there is going to save money for the country in the long- term and keep people living a healthie

the lilly products. >> and then where do we go now?o snuff out pfizer's oral one the next big one and heard people say pull in your horns on these drugs what they can do if we reach more of a consumer slowdown? the next round who might be a stock to benefit or stick with tech with what's working? >> stick with lilly and novo because they're working and have a huge moat in the market. a clear challenge, marketability, even for stalwarts, have data and a pipe line of products beyond wegovy, zepbound and mounjaro. remember, lilly has oral data coming next year and poised to take share in that space. though i still love lilly and novo when it comes to obesity. not that there's not other names to play. pfizer under value. steady eddy quarter after the turbulent year. see what there's. again, lilly is becoming the g.o.a.t. in the obesity. >> that's a great line. let's talk -- a little bit about the -- the potential of these drugs to be helpful in other areas, like cardiovascular health? maybe even alzheimer's? >> for sure. >> how do you fact

lilly plans to show the data to insurers.epatide helps people do more than just lose weight. >> does tirzepatide actually not only keep you thinner but keep you healthier? and we're beginning to learn it keeps you healthier. so, i think we need to argue for that. and both the federal government doesn't pay for these, many employers don't. they should. this is going to save money for a country in the long term. and keep people living a healthier, longer life. >> lilly keeping people on tirzepatide for three years in the trial and then having them actually go off the drug. some people regain their weight and saw their blood sugarses keep up. ricks is saying this treats chronic diseases. >> "money movers" begins right after this. new projects means new project managers. you need to hire. i need indeed. indeed you do. when you sponsor a job, you immediately get your shortlist of quality candidates, whose resumes on indeed match your job criteria. visit indeed.com/hire and get started today. >>> good tuesday morning again. welcome

angelica has details on what's going on. >> lilly will make vials of zepbound available through lillyre are a few things to know about this. it's only for people whose insurance won't cover the drug, think people on medicare. the price is about $500 a month out of pocket depending on the dose. you need a prescription and then you fill it directly with lilly. only two of the lowest strengths of the drug are included. the medicine will come in vials. that means you need to draw it up with a syringe and inject it with a needle. typically zepbound comes in a pen you would administer with a click of a button. the pen is a bottleneck to manufacturing the glp-1s. lilly telling us the main thing is to increase supply, reach people on medicare and other insurance providers that won't pay for obesity drugs and trying to steer people away from compounded glp-1s. the drugs all over the internet. there was initially some concern about lilly having the price on this drug, but remember, there's usually a big difference between the list price of a drug and the net price after the rebates, so the diff

eli li eli lilly announcing it will offer low-dosage versions, instead of the pens. patients with a prescription not covered by insurance will be able to buy a month's supply for $399. and the 5-milligram dose for $549, directly from eli lilly. >> we've been frustrated. we can't meet the incredible demand for this medicine. and this is a way we can do that more quickly, but also, we're trying to meet the needs of patients who don't have insurance coverage. >> reporter: but, to be clear, this won't help people who are on higher doses of zepbound. >> well, if they have coverage in their insurance, there's no change for them. if they don't have coverage with their insurance, they can talk to their doctor go moving to the five milligram dose. >> reporter: a former police officer is one of those patients paying $1100 a month. that's a lot of money a month. how are you able to do it? >> i'm putting it on credit cards, honestly. >> reporter: you're going into debt to take this medication. >> i am, yes. >> reporter: his doctor wants him on a higher dose starting next month.

that's why there's a premium for the real think made by lilly. >> stephanie joins us now in studio.cult is for the patients to give the shots with the vials? >> well, there are other medications that use syringes like insulin and fertility drugs but it is definitely a little bit more difficult. patients have to actually draw the dose into a syringe, and for some people that's kind of a daunting thing to have to do. >> all right. stephanie gosk with the new developments tonight. thank you. >> you're welcome. >>> coming up, why some are seeing a champagne super nova in the sky tonight. what oasis just told fans. (vo) you might be used to living with your albuterol asthma rescue inhaler, but it's a bit of a dinosaur, because it only treats your symptoms, not inflammation. treating both symptoms and inflammation with rescue is supported by asthma experts. finally, there's a modern way to treat symptoms and asthma attacks. airsupra is the first ever dual-action rescue inhaler that treats your asthma symptoms and helps prevent attacks. airsupra is the only rescue fda-approved to do both.

see a markets share shift from eli lilly products in the united states.ome analysts are actually forecasting a 50/50 split between these two companies in terms of the market share in the united states. it is important to take a step back and also look at what other news we obtained in this space. recently, wegovy is less effective, i should say, than actually zepbound. let me share the numbers with you. patients that were on the highest dose of zepbound lost 21% of body weight over a period of 72 weeks. however, when you compare the results for wegovy patients, they lost 15% of body weight over a period of 68 weeks. so the efficacy here is important because it could change the reputation of novo's drugs in the united states. just a final point to say when you look at the share price reaction recently, both eli lilly shares and novo nordisk have also been hit by news that roche had seen positive trials for the weight loss pill. that would also be a huge change here for the weight loss drug market. i want to share this kpcomment with you when i had the chan

that's why there's a premium for the real thing made by lilly. >> stephanie joins us now in studio.how much more difficult is it for the patients to give themselves the shots with the vials? >> well, there are other medications that use syringes, like insulin and fertility drugs, but it is definitely a little bit more difficult. patients have to actually draw the dose into a syringe, and for some people, that's kind of a daunting thing to have to do. >> all right. stephanie gosk with the new developments tonight. thank you. >> you're welcome. >>> coming up, why some are seeing a "champagne super nova" in the sky tonight. news of the '90s band known for their big ballads and public breakup. what oasis just told fans. nova in the sky tonight. what oasis just told fans. (vo) you might be used to living with your albuterol asthma rescue inhaler, but it's a bit of a dinosaur, because it only treats your symptoms, not inflammation. treating both symptoms and inflammation with rescue is supported by asthma experts. finally, there's a modern way to treat symptoms and asthma attacks. airsupr

we will see what happens when lilly reports next week.oved for heart health. we are looking at phase three results for the drug cagrisema. we are waiting for the trial that will test zepbound against wegovy. the biggest readout outside of novo and lilly is amgen with encouraging phase two results. we have not seen the data yet. we will get into this and more with the interview for pro subscribers available on cnbc.com/pro later today. >> this is an interesting discussion. it has been comedominating the healthcare chatter. why is there still so much optimism with the drugs running massively? >> we are at the early stages of the market. there are two drugs available, but so much room left to go. this could be a possible $100 billion plus market. there is, of course, the u.s. and other countries around the world. we want to see pills. we want to see different amounts of weight loss. there's a lot of room left to run. that's why you are seeing so many companies getting into the space and still a lot more work from novo and lilly. >> angelica

shares of eli lilly down in sympathy today. lilly reports t. your take on either?not report the kind of sluggish growth that, you know, novo did. >> or what? >> well, the stock is -- >> sound like my dad, you better not. >> just really quickly, 3% growth year over year on 24% sales growth, so, those expenses are becoming a problem here, so, that's the take on lilly. just the last thing, we've been talking about this for a little bit, you know, 50% of the scripts are insurance covered. so, this is a very high priced consumer discretionary item right now. >> lilly has a real chance to trade down -- and we've been saying this for awhile on the way up, which was wrong, but now since it made the all-time high. 730. and by the way, do you not watch television? it's wegovy. they have people singing in choruses and -- >> have you not seep me walking around? i'm clearly not on any weight loss drug. okay, i'm clearly not taking said product. it should be obvious to you. guy. >> not particularly. >> wegovy. julie -- who ways to look at this. novo -- i don't want to say proble

pfizer is down 11% in the past five years, lilly's up 753%.s. it's staggering. it's just like beyond comprehension almost, isn't it? >> it's unbelieve -- it's unbelievable, i mean, i think about it every day. you got, eli lilly is now the largest drug company by a mile. it's three or four times bigger than pfizer at this point. >> could add up to all of them? >> all of them, yeah. pfizer used to be the company that we kind of started with in pharma from a size standpoint, but now it dwarfs lilly. this is such an unbelievable story your lilly and novo nordisk. you don't have to do much work here, you know what the pricing is, it's not that difficult. >> was is saerendipity, or was t a lock? when somebody decided, the first glp for diabetes, did they notice, wow, a lot of weight is coming off? is that really how it happened? and now we've got a trillion-dollar drug company? >> yeah, that's definitely part of it as an industry, biotech and pharma has been working on obesity for a while. >> right. >> it's just the prior generation had side effects

and love for lilli. finding another potential use for zepbound weight loss drug, helping it to snap an illusive gain in today's session. i'm melissa lee, coming to you live from studio b at the nasdaq. on the desk tonight -- karen finer mann, dan nathan, guy adami and carter worth. >>> we've got team coverage on the results. snap's massive drop. pippa stevens is covering intel. kate rooney is digging into amazon's quarter. but we start off with steve kovach who has the details on apple's beat on the top and bottom line. steve? >> hey there, mel. and not just a beat on the top and bottom lines. they return again to top line sales growth. that is one of the big headlines on this report. let's go over the results here, though. eps was a beat. $1.40, street was looking for $1.35. revenue, a beat at $85.78 billion, and that is up 5% year on year, about where apple had guided to last quarter. and iphone revenue, a beat here again. that is $39.3 billion, and services revenue, $24.21 billion. slightly beating ex

well, eli lilly is like 13% of the health care etf right now. weighted health care is kind of softer than that. you have to kind of know what you're using as a benchmark when it comes to these things. >> like discretionary. okay, discraigary is great. well, amazon and tesla are such a huge part of that. >> or they're weighing it down at times. i keep thinking that not to say you have more payback to do, but it feels like we wouldn't be too far once we rebuild toward the highs if we get there, and people are kind of celebrating. there's been a little bit of fomow in the market in the last few days as the streak got to seven or eight days. massive volumes. call option, that kind of stuff really going. the three times leverage nvidia etf, which exists, has billions of dollars in assets under management. so it's not that far below the surface. even though we had a good scare to rekindle that type of activity. makes it interesting going into late august. >> thing about target, coming too. after what we got from the retail sales number and then walmar

the single-use vials will only be available on the eli lilly telehealth platform lilly direct. >>> policyrovement company scaling back its diversity, equity, and inclusion policies. it comes after several other companies recently did the same. the change has been in response to the supreme court's decision to outlaw affirmative action in college admissions and a wave of conservative backlash on line. >>> and pizza hut is trying to make your next move a little easier. the restaurant chain is now offering customers a free moving box table. it's a mini cardboard table which you can rest your pizza on. the limited time offer is only available to customers in dallas, charlotte, and orlando. >>> that's your cbs "moneywatch" report for this wednesday morning. i'm shanelle kaul, cbs news, new york. >>> ahead, stop the show. a country music singer halts his concert to help a fan. ert to he. i'm jimmy dean and only one thing could make a morning like this any nicer... a hearty, hefty, good tasting breakfast, with eggs, bacon, sausage, cheese and tators. and when you finished, you know you had somet

he says in part that lilly's -- lilly's modest step forward by loring the prices is helpful, howeverns including mounjaro, the diabetes drug as well as novo nordisk and ozempic and wegovy and this puts pressure to lower the cost of the drugs and eli lilly to lower the costs of other med kagds, as well. >> berkeley lovelace, jr., thank you. always good to see you on the show. meantime, speak of costs, hit a new record in june. the value of u.s. single-family homes show prices were up 5.4% more than they were just this time last year. the biggest jump was right here in new york up 9%, san diego and las vegas not far behind and important to the 2024 presidential campaign, affordability is down. >>> still ahead, why donald trump continues to blast an upcoming debate date and how the harris campaign is responding. stay close. more "chris jansing reports" right after this. chris jansing " right after this ♪ (woman) c'mon c'mon ♪ (man) yes! ♪ (vo) you've got your sunday obsession and we got you. now with verizon, get nfl sunday ticket from youtube tv on us and get every out-of-market sunday

eli lilly said the move will increase consumers access to is about.sing the price of its flagship playstation 5 injapan by 19%. starting from september the second, the console will be sold for around $550. the company says it has been hit by a severe external environment. playstation 5 is around four years old and sales of the device fell in the most recent quarter. turning now to the uk where one company is trying to make budget flip phone is popular again. make budget flip phone is popularagain. hmd make budget flip phone is popular again. hmd says the features on its flip phone's could help parents trying to cope their children's access to harmful social media contents and they've tied up with barbie to make the phone is more appealing. the bbc is added looks at whether back to basic phones are the way forward. barbia, 65—year—old brand which was given a new lease of life last summer when the star—studded film hit cinemas is back again. this time, it's in the form of a flip phone made by the mobile phone company, hmd, the same budget brand behind n

eli lilly, ceo, spoke about the new options to nbc news. by adding vials today, we can expand supply for the lowest doses. the most commonly used doses two and a half and five milligrams. but also we're trying to meet the needs of patients who don't have insurance coverage if they have coverage in their insurance. there's no change for them. if they don't have coverage with their insurance and they're buying it out of pocket. they could talk to their doctor about moving to the five milligram dose. now you can watch more of that interview with eli lilly ceo coming up right now. and nightly news at 630. well, newly released census data is showing which cities in the united states are drawing the most lgbtq families. and san francisco tops the list. that's the census numbers from 2020. gay male couples tend to gravitate toward big cities on the coasts, while lesbian couples tend to prefer smaller cities and towns. san francisco had the largest share of male same sex couple households, at almost 6%. take a look. according to the data, just rele

eli lilly said the move would increase us consumers' access to zepbound.mmer, barbie, the movie dominated the box office and popular culture. now, makers of the nokia phone, hmd global, have teamed up with toymaker mattel, to create, a barbie flip phone, as many parents grapple with how to give their children our technology editor, zoe kleinman has been taking a look. barbie, a 65—year—old brand which was given a new lease of life last summer when the star—studded film hit cinemas, is back again. hi, barbie! this time it's in the form of a flip phone made by the mobile phone company hmd, the same budget brand behind nokia. it's a feature phone, also sometimes called a dumb phone, meaning there's no access to social media and it can only perform basic functions like texting and calling. as concerns about the pressures of digital life on young people grows, hmd hopes devices like this might prove popular with children and indeed adults looking for a digital detox. i asked the firm whether the handset will live up to expectations among young people as it trie

eli lilly taking a breather today after a scorching two-day rally. the past week. that's after hiking full-year guidance on demand for its weight-loss drugs. deutsche bank upgrading that stock to buy calling it a, quote, low beta, high-growth unicorn. joining me with the outlook on the stock and the bio pharma case is michelle ross. welcome back. >> thank you so much for having me. >> what is our big takeaway from glps, whether novo or lili? >> i think novo set the stage. i think it caused a little concern in the midst of what is a tremendous growth market in anticipation of this growth to what is the pricing dynamic on these specific drugs, this class of drug. that was a fair question i think as you bring in more exposure to patients, when you include medicaid coverage and medicare coverage. you are talking about potentially different price points. however, when lilly came out and discussed their view of the market, what they are seeing currently, i think they really did dispel any major fear that we were going into really a reversion to pushing on

>> yeah, so lilly hopes that this will stop the shortage as well.ctor pens are what are thought to have caused a lot of the shortages. lilly said it is very complicated to manufacture the auto injector pens. right now they're saying they will be able to alleviate the shortage right now it but remains to be seen. as we know the medications are incredibly popular as women. zinhle. >> certainly in high demand. berkeley lovelace jr. thank you so much. >>> to a food fight between two of the biggest supermarket chains and the government that could have an impact on your wallet. albertson's and kroger want to merge their companies, but federal regulators do not want that deal to go through. now the case is in the hands of a judge. nbc news senior business correspondent christine romans has the details. >> reporter: it is a major food fight. the u.s. government is trying to stop in court a major merger between albertson's and kroger. these are the second and fourth largest grocery store chains in the united states, and maybe you don't recognize those two na

now we wait for eli lilly to report. it's thursday, august 8th, 2024 and "squawk box" starts right now. ♪ ♪ >>> good morning. welcome to "squawk box" here on cnbc. we are live from the nasdaq market site in times square. in a rainy times square. i'm andrew ross sorkin along with joe kernen. becky is off today. we have the u.s. equities to talk about and to talk about how they actually haven't improved that much all around here. dow jones industrial average off 113 points this morning. nasdaq looking to open down 25 points. s&p 500 looking to open down 15 points. this all after yesterday's market failed to hold what was an early rally and the averages saw the gains melt away as the afternoon progressed. dow on pace for the worst week since march last year. take a look at treasury yields right now. we will show you the ten-year and two-year. i always say the ten-year and two-year. they don't say the five-year and 30-year which we also do. take a look at bitcoin. that is gaining ground. now it's uncorrelated to the nasdaq.

i sat down with eli lilly's ceo. who have been looking for a way to access and afford our weight loss medication zepbound. now they can go to lilly direct with a prescription from their doctor and phone, access the drug in a vial form. >> whit: the ceo dave ricks saying this will make the drug more available and affordable, allowing people to purchase it without insurance. >> we're working to build more supply but in the mean time we can release these vial forms that are 2 1/2 and 5 milligram dose that are going to be more available and at a lower price. about half the price of our auto injected form and the competitor products. this is launching at $349 for the low dose and $549 for the high dose. that's a significant discount. >> whit: you mean for a monthly amount? >> yes. >> whit: that's still a lot of money. people would be paying a lot. that's like a car payment for some people. can you explain why the cost is still so high? >> well, we're, of course, researching and developing medications. we invented this pro

eli lilly says this version of bound will help with the increased demand for weight loss medications. and later this morning on gma, abc news anchor whit johnson talks one on one with eli lilly ceo david ricks to discuss the direct to consumer version of bound. you can watch the full interview at 7:00, right after abc seven mornings. >> thanks, amanda. 507 this morning we're in store for another warm to hot day. today's the hottest day on the seven day forecast. warm sunshine in the city today will hit 74. 84 in oakland today. sunny and hot in the south bay. 93 in san jose. it's a hot august day in walnut creek hitting about 97 with those sunny skies. hello okay, a live look at the airport this morning. you could see it is quiet out there. we have clear skies above the airport. 59 degrees right now in oakland. great visibility, high humidity and the winds are very light. so let's take a look at the travel forecast. it is warm across our desert today 109 in phoenix, 103 in vegas to the north in the pacific northwest seattle. some morning showers giving way to sunshine, a high of 67 deg

the ceo of drugmaker eli lilly tells us about the company's announcement.hat could help some users. and we've got the right stuff for back to school. plus, tennis great andy roddick here giving us an insider's look at the u.s. open. and you will see this all on gma. >> you just really triggered an old memory of mine just by looking at that video of the albertsons, because it said osco pharmacy. which brings me back to chicago and jewel osco. >> yes, i lived right by a jewel parking lot, and i always walked past it and it's always in my head because i remember going to jewel for the first time. my stepdad is from chicago and being like, what is this? >> what is it? >> me too. we're so regional with our grocers. >> we really are. jewel osco is kind of the store if you live in the chicagoland area. okay and there was a osco. that was right by me. okay and there was a famous woman in there who would sing everything that you purchased until she would get the sensitive items, and then she would delete that. but it was so noticeable that she stopped singing that e

but overall, jim, like you said, this is eli lilly's response to try to reach that high demand. that's out there, especially among patients who again, don't have the insurance coverage for this medication, but they don't qualify for the assistance program, so they are paying all the costs out of pocket. >> and do we think that some of these other pharmaceutical companies are going to try to follow suit and rollout these singer no dose vials. what do you think that's a great question. i think if we see that eli lilly is successful with this approach, i would not be surprised if other companies like the pharmaceutical companies behind semaglutide, like ozempic and wegovy follow suit, zepbound itself is a terse appetite weight loss drug, but the semaglutide are eating equally important. these include ozempic and wegovy and prescriptions specifically for semaglutide have gone up 40 fold in the past five years. jim. so that's the demand that we're seeing right now. and i will be interested to see what the future holds. if we do see other companies it's like you said, follow this same

brianna drug maker eli lilly is now offering cheaper single-dose vials of its popular weight loss drugszepbound. this might help with endless shrimp by the way, this is promising news for for anyone wanting to try the drug, but who can't afford it. eli lilly says the move single vials will actually allow for much greater supply of zepbound amid shortages brought on by its high popularity. we have cnn's jacqueline howard with us now on this story. all right, so how much is this going to cost? and who would qualify for a discount here well, brianna, this is specifically for patients who are paying the full out-of-pocket cost. >> and these are for patients who did not qualify for eli lilly's assistance program. now, how much these new starter doses will cost. we know that the for weeks supply for a supply of two 2.5 milligrams in each file that will be $399 a four-week supply of vials containing five milligrams will be $549. these costs are much lower than what the original list price was four is that bound, which was $1,059.87. so these are the differences were talking about here with the

looking at individual stocks this morning, i want to see eli lilly.in up another 1%. lauren, do they have more good news on the weight loss drug? lauren: the miracle drugs. yeah, they cut diabetes risk by 94% and patients who are either overweight or pre-diabetic. they also led to a 23% weight loss over three-years. that's a long time. this is the longest study yet on the glp-1s. three-years, and you lose 23% of your body weight. so what this shows is the drugmakers looking to extend the use of their obesity drugs, so now diabetes, sleep apnea, heart conditions eli lilly at 9.34 up 1.5%. stuart: home improvement store lowe's i know they reported this morning the stock is down just a fraction. how do they do? lauren: i think we knew it wasn't going to be the best report. fewer customers are fixing up their homes. the company blames weather. it was too hot for lawn projects in the summer. their revenue and their same-store sales in the quarter each fell by more than 5% and they cut their annual profit forecast but like i said, weak but expected because

we know eli lilly could be a competitor.his is a crucial time where you have to make investment decisions when prices are higher and you have more cash coming in. is that how you view it? lars: yes, to put a bit of color around it, the same forecast predicts that there will be one billion people living with obesity in 3035. we are perhaps serving one or 2 million of those today, so there's a huge market and there's a place for more, and then you are right that in most markets when you get more competition and also over time, pricing moves down because you start treating those who accept the higher price one in the u.s. and that's commercial insurance and then you get broad access and you get your patient's payload price. so, if you just take our leading diabetes product in the u.s. since launch, in 2018, the price we get is some 40% lower than when we launched. that's also not mentioned in the politics. instead the list price is mentioned. which is what we put in our account. francine: the u.s. is such a large market would y

eli lilly is up 3% today.is here with that story. >> lilly says they cut the risk of diabetes by 94%. this three-year study is showing the drug can help people with prediabetes and stop them from getting worse. one in three americans have prediabetes. there aren't any drugs to treat it. this could open up another way to use tirzepatide. >> not only do you lose weight, but that when you do, on this medicine, it converts to health benefit. this is our fourth study this year that does such a thing. here now we have pre-diabetes not turning into diabetes. last month, congestive heart failure. in april, we had sleep apnea. >> rick is telling us the company plans to talk to regulators about next steps. the study also showing people kept the weight off for three years. that could help support long-term use of the drug. lily is trying to convince this drug is worth paying for over the long run and this is another way to do that, kelly. >> indeed it would be. angelica, thanks. let's see if victoria thinks this is a buy

jonathan: punchy upgrade, eli lilly had seen 42.4 to 43.6, the latest on eli lilly, up in the pre-markets surveillance this morning, when colleen turns to cold. >> looks to me that the labor market is cooling up significantly. every time that has happened, we get a recession, so there is a lot of risk out there. the problem here is on the market deteriorates, confidence declines, and that can be self reinforcing. jonathan: a light week of data has all eyes on jobless claims. estimate calling for 240,000 claims. sara wolf of morgan stanley saying the economy is on us soft landing -- soft landing path, writing that demand for labor is softening. the most recent payroll print showed a meaningful slow down, but the recent trend remains firmer. we expect and employment rate of 4.2% by q4 and 5.4% by the end of next year. sarah joins us for more. that is a constructive outlook when people are worried where this is going. where does that constructive outlook come from? sarah: the unemployment data is noisy. it is not the first time we've gotten a week payroll print around the hundred thousand ma

we know of eli lilly. we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that is often not mentioned in, say, the political

resmed, eli lilly is on the list, 958 for lilly. nasdaq, am a md, sirius radio, astrazeneca.t 3. 86. price of gold down $8. bitcoin, $662-- 62,300. oil, $76.77. there you have it. nat gas below $2. the average price for a gallon of regular, $3.35. and we always like to tell you this, in california regular average as $4.61. >>> donald trump trashing the biden-harris foreign policy for putting network danger. >> america's future -- america in danger. >> america's future is under threat like never before. i don't think we've ever been closer to world war iii than we are now. stuart: christian whiton here with answers. biden was spotted in delaware looking tired, frail and confused. who's running the country? if maybe mike huckabee is as a confused as the rest of us. he is going to be the on the show. mark zuckerberg says the administration pressured him into censoring covid-19 content. he says going forward meta won't bend to politics. former parler chief executive john mats if -- has more on this, he's next. ♪ i got this crazy feeling deep inside -- ♪ when you called and asked

shares of eli lilly dropping and hims & hers dropping. we're heading towards the close.ike it's going to be a little bit of a nasty one, too. "closing bell" is coming right back. >>> lilly sharing information about their weight loss drug. the ceo david ricks saying zepbound should come off the fda shortage list soon. hims & hers said they will start sending the compounded versions of novo's wegovy. a lilly spokesperson said ultimately the fda will decide when to update the shortage list. we'll let you know when we learn more. thank you. >> amazon and intel reporting at the top of the hour. we are less than an hour away from apple's results. we'll let you know a othllf e key themes you need to know from those key names. you founded your kayak company because you love the ocean- not spreadsheets. you need to hire. i need indeed. indeed you do. indeed instant match instantly delivers quality candidates matching your job description. visit indeed.com/hire they started as dreamers. but today, they're stars. follow every moment of team usa on the network that brings you legend

. >> novo nordisk in eli lilly had the blockbuster drugs in a recent study out of uk suggested an olderlp-1 drug novo could slow the progression of alzheimer's disease. his noxious weight loss, there's more research out of the uk, we showed that the shingles vaccine may delay the onset of dementia as well, do the relatively small studies in incremental results but alzheimer's is a devastating disease and people are paying attention and looking for help. meanwhile the adjacent sector of biotech as had a really bad few years, what is going on you see signs of hope? >> it's been terrible if you look at xpi or biotech ets over the last five years up about 15% and 65 percentage points it's been a terrible sector, it's more of a rate trade biotech's are speculative stocks in as a drug works there is a lot of smaller capitalization into thirds of the biotech stocks lose money and below 5 billion at the speculative sector, when rates go down it is cheaper to speculate. jack: you recommend the index rather than trying to pick winners and losers. >> you can even, aaron judge hits a homerun 8% of

we know of eli lilly. we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 30-35. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing moves down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that is often not mentioned in, say, the political debate.

. >> reporter: a senior biologist with the eli lilly company he is familiar with the medical marvel flowingath the horseshoe crab shells. >> this is purified horseshoe crab blood. >> reporter: limulus amoebocyte lysate is made from the bright blue blood of horseshoe crabs is used to detect dangerous endotoxins in medicine. >> have all of us benefitted? >> sure, if you have gotten a vaccine. anything that comes into contact that medicine has to be shown to be free of endotoxins. >> reporter: while they can be found everywhere, you don't want it to put him straight into your bloodstream. it could make you sick or potentially kill you. horseshoe crab blood reacts to the presence of endotoxins. which is why for decades it has been used to test for medicines, syringes, and implantable medical devices. before this method was developed scientists tested with live rabbits. >> every pharmaceutical company, every manufacture, everyone is using ths? >> anyone making an injectable is using this. so it's widely spread. >> reporter: the collecting and bleeding is done by laboratories. while live crabs ar

. >> novo nordisk in eli lilly had the blockbuster drugs in a recent study out of uk suggested an olderrug novo could slow the progression of alzheimer's disease. his noxious weight loss, there's more research out of the uk, we showed that the shingles vaccine may delay the onset of dementia as well, do the relatively small studies in incremental results but alzheimer's is a devastating disease and people are paying attention and looking for help. meanwhile the adjacent sector of biotech as had a really bad few years, what is going on you see signs of hope? >> it's been terrible if you look at xpi or biotech ets over the last five years up about 15% and 65 percentage points it's been a terrible sector, it's more of a rate trade biotech's are speculative stocks in as a drug works there is a lot of smaller capitalization into thirds of the biotech stocks lose money and below 5 billion at the speculative sector, when rates go down it is cheaper to speculate. jack: you recommend the index rather than trying to pick winners and losers. >> you can even, aaron judge hits a homerun 8% of the ap

we know of eli lilly. we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate.

ademÁs, la versiÓn de pound, que estÁ lanzando eli lilly elimina las plumas auto inyectoras de dosisivienda. los precios de las casas en todo el paÍs alcanzaron cifras rÉcord con un aumento a nivel nacional del 5.4% con respecto a junio de 2023 y con un precio promedio de 362.000 $. la situaciÓn tambiÉn es grave para los inquilinos. en promedio, a nivel nacional se gastan mÁs del 27% de los ingresos familiares en pagos de renta. ciudades como nueva york, miami y los Ángeles encabezan la lista de los alquileres mÁs costosos. sonia aparicio sÁnchez amplÍa la informaciÓn porque se estÁ sobrepasando el lÍmite. >> ingrid vÉlez por fin, despuÉs de muchos aÑos en los estados unidos, pudo comprar su casa en el sur de la florida. sin embargo, segÚn ella, el remedio resultÓ peor que la enfermedad afecta su bolsillo muchÍsimo, porque realmente hay muchas cosas. >> no es solo pagar la renta de tu casa o el mortgage viene. tienes que pagar luz, tienes que pagar agua. >> el estudio realizado por moody's analytics analizÓ los precios en cinco grandes ciudades desde el 2019 y encontrÓ que las vivien